EP0859771A4 - Substituted pyridyl pyrroles, compositions containing such compounds and methods of use - Google Patents

Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Info

Publication number
EP0859771A4
EP0859771A4 EP96942022A EP96942022A EP0859771A4 EP 0859771 A4 EP0859771 A4 EP 0859771A4 EP 96942022 A EP96942022 A EP 96942022A EP 96942022 A EP96942022 A EP 96942022A EP 0859771 A4 EP0859771 A4 EP 0859771A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
compositions containing
substituted pyridyl
pyrroles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96942022A
Other languages
German (de)
French (fr)
Other versions
EP0859771A1 (en
Inventor
Laszlo Stephen E De
Linda L Chang
Dooseop Kim
Nathan B Mantlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605158.6A external-priority patent/GB9605158D0/en
Priority claimed from GBGB9612062.1A external-priority patent/GB9612062D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0859771A1 publication Critical patent/EP0859771A1/en
Publication of EP0859771A4 publication Critical patent/EP0859771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
EP96942022A 1995-10-31 1996-10-30 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use Withdrawn EP0859771A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15565 1979-02-26
US710095P 1995-10-31 1995-10-31
US7100P 1995-10-31
GB9605158 1996-03-12
GBGB9605158.6A GB9605158D0 (en) 1996-03-12 1996-03-12 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US1556596P 1996-04-18 1996-04-18
GBGB9612062.1A GB9612062D0 (en) 1996-06-10 1996-06-10 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
GB9612062 1996-06-10
PCT/US1996/018539 WO1997016442A1 (en) 1995-10-31 1996-10-30 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EP0859771A1 EP0859771A1 (en) 1998-08-26
EP0859771A4 true EP0859771A4 (en) 2000-03-15

Family

ID=27451424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96942022A Withdrawn EP0859771A4 (en) 1995-10-31 1996-10-30 Substituted pyridyl pyrroles, compositions containing such compounds and methods of use

Country Status (4)

Country Link
EP (1) EP0859771A4 (en)
JP (1) JPH11514651A (en)
AU (1) AU702887B2 (en)
WO (1) WO1997016442A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
BR9710352A (en) 1996-07-11 1999-08-17 Pfizer Pyridylpyrrole compounds
DE69728688T2 (en) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLE AS AN ANTI-FLAMMING AGENT
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP1314732A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
AR038955A1 (en) * 1996-12-05 2005-02-02 Amgen Inc PIRIMIDINONE AND PIRIDONA SUBSTITUTED COMPOUNDS AND METHODS FOR USE
HUP0001140A3 (en) * 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
PL199893B1 (en) 1997-06-12 2008-11-28 Rhone Poulenc Rorer Ltd Imidazolyl-cyclic acetals
WO1999001423A1 (en) * 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
JP2001521934A (en) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Aromatic heterocyclic compounds as anti-inflammatory drugs
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
RU2204390C2 (en) * 1998-01-14 2003-05-20 Ниппон Синяку Ко., Лтд. Activators of potassium channels
US6232322B1 (en) 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002514635A (en) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション Biphenyloxo-acetic acid useful for treating insulin resistance and hyperglycemia
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
DE19847823A1 (en) * 1998-10-16 2000-04-20 Aventis Pharma Gmbh New 3-(Hetero)aryl-5-aminosulfonyl-1,2,4-thiadiazole derivatives useful as inhibitors of IL-1beta production in treatment of e.g. leukemia, septic shock, hepatitis, AIDS and diseases of locomotor system
ATE258055T1 (en) 1998-11-04 2004-02-15 Smithkline Beecham Corp PYRIDINE-4-YL OR PYRIMIDINE-4-YL SUBSTITUTED PYRAZINE
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ES2251360T3 (en) 1999-03-12 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. AROMATIC HETEROCICLIC COMPOUNDS IN QUALITY OF ANTI-INFLAMMATORY AGENTS.
AU4315100A (en) * 1999-04-28 2000-11-17 Sankyo Company Limited Preventive or inhibitory agents for hepatopathy
US6310081B1 (en) 1999-05-10 2001-10-30 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
CA2374559A1 (en) * 1999-05-14 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
ES2253233T3 (en) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. PROCEDURE FOR SYNTHESIS OF UREA HETEROARIL SUBSTITUTED COMPOUNDS.
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2003509420A (en) 1999-09-14 2003-03-11 メルク フロスト カナダ アンド カンパニー Carboxylic acids and acylsulfonamides, compositions containing such compounds, and methods of treatment
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
MXPA02004879A (en) 1999-11-16 2002-08-30 Boehringer Ingelheim Pharma Urea derivatives as anti inflammatory agents.
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003528043A (en) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
ES2436610T3 (en) 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
JP2004513935A (en) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ Glucagon antagonist / inverse agonist
BR0206533A (en) * 2001-01-18 2003-12-16 Sankyo Co Compound, pharmaceutical composition, and use of a compound
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004531571A (en) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Carbamate and oxamide compounds as inhibitors of cytokine production
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
HUP0401644A3 (en) * 2001-08-28 2008-03-28 Leo Pharma As Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
JP2005505562A (en) * 2001-09-05 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Pyridylfuran and pyrrole as Raf kinase inhibitors
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
RU2005108586A (en) * 2002-09-27 2005-10-10 Янссен Фармацевтика Н.В. (Be) 3,4-DISPLACED PYRROLES AND THEIR APPLICATION FOR TREATMENT OF INFLAMMATORY DISEASES
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2004312001B2 (en) 2003-12-19 2009-08-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
PL1756064T3 (en) 2004-06-04 2008-11-28 Merck Sharp & Dohme Pyrazole derivatives, compositions containing such compounds and methods of use
CA2574147A1 (en) 2004-07-22 2006-02-09 Linda Brockunier Substituted pyrazoles, compositions containing such compounds and methods of use
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
PL1931350T5 (en) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
AU2006294579A1 (en) 2005-09-27 2007-04-05 Myriad Genetics, Inc. Pyrrole derivatives as therapeutic compounds
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AU2007229850A1 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2649543A1 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
JP2009537525A (en) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ES2400695T3 (en) 2006-07-17 2013-04-11 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008030466A1 (en) 2006-09-05 2008-03-13 Amgen Inc. Phthalazine, aza- and diaza-phthalazine compounds and methods of use
BRPI0717097A2 (en) 2006-09-21 2013-11-26 Novartis Ag PIRROL DERIVATIVES USEFUL FOR TREATMENT OF CYTOKINE MEDIATED DISEASES
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ATE542818T1 (en) 2006-10-11 2012-02-15 Amgen Inc IMIDAZO AND TRIAZOLOPYRIDINE COMPOUNDS AND METHOD OF USE THEREOF
EP2116530B1 (en) * 2007-02-26 2012-11-14 Santen Pharmaceutical Co., Ltd Novel pyrrole derivative having ureide group and aminocarbonyl group as substituents
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
US8420649B2 (en) 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
US8455495B2 (en) 2008-08-29 2013-06-04 Amgen Inc. Pyridazino-pyridinone compounds and methods of use
WO2010042646A1 (en) 2008-10-10 2010-04-15 Amgen Inc. Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CA2787360C (en) 2010-02-03 2019-03-05 Takeda Pharmaceutical Company Limited Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
IT201800003680A1 (en) * 2018-03-16 2019-09-16 Univ Degli Studi Di Siena ANTIVIRAL COMPOUNDS AND USES OF THEM

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (en) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (en) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267185A (en) * 1980-04-09 1981-05-12 E. I. Du Pont De Nemours And Company Antidepressant pyrrolylpiperidines, their pharmaceutical compositions and method of use
US4652582A (en) * 1985-01-09 1987-03-24 E. I. Du Pont De Nemours And Company Antiinflammatory-2-halo-4,5-diarylpyrroles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2113861A1 (en) * 1970-11-16 1972-06-30 Pfizer
EP0034798A2 (en) * 1980-02-19 1981-09-02 E.I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONAKAHARA, TAKEO ET AL: "One-pot synthesis of pyrroles from N-silyl-1-azaallyl anions", HETEROCYCLES ( 1993 ), 35(2), 1171-84, 1993, XP000857214 *
See also references of WO9716442A1 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of 2,4,5-triaryl-substituted pyrroles. II. Oxidative dimerization of 4,5-diphenyl-2-mesitylylpyrrole", J. HETEROCYCL. CHEM. ( 1989 ), 26(2), 489-92, 1989, XP000857212 *
SILVESTRI, G. ET AL: "Electrochemical oxidation of substituted pyrroles. IV. The influence of soluble bases", J. HETEROCYCL. CHEM. ( 1992 ), 29(7), 1847-50, 1992, XP000857213 *

Also Published As

Publication number Publication date
AU702887B2 (en) 1999-03-11
JPH11514651A (en) 1999-12-14
EP0859771A1 (en) 1998-08-26
WO1997016442A1 (en) 1997-05-09
AU1120897A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
EP0859771A4 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0871444A4 (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en) Substituted aryl pyrroles, compositions containing such compounds and methods of use
SI0807111T1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same
PL323470A1 (en) Application of n-propargil-1-amidoindane (r)-enantionmer, its salts and compositions containing same
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
AU6613996A (en) Heterocyclic compounds and pharmaceutical compositions containing them
EP0811595A4 (en) Hydrochalcone derivatives, comestic compositions containing the same, and processes for the preparation of both
EP0948257A4 (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
AU7529096A (en) Substituted aryl pyrroles, compositions containing such compounds and methods of use
PL324436A1 (en) Novel derivatives of oxazolydinone, method of obtaining them and therapeutic agents containing such compounds
IL112443A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL108800A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
AU1841195A (en) 1-beta -methyl-carbapenem, compositions containing same and methods of use
AU7986098A (en) 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
IL106041A0 (en) Heterocyclic compounds,their preparation and pharmaceutical compositions containing them
HU9503318D0 (en) Arthropocidal compounds, compositions containing them and process for their preparation
IL107890A0 (en) Substituted n-hydroxycinnamamides, processes for their preparation, compositions containing them and their use
GB9814269D0 (en) 9a-Aza-3-ketolides, compositions containing such compounds and methods of treatment
GB9605158D0 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
GB9612062D0 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
PL329053A1 (en) Novel derivatives of oxazolydine, method of obtaining them and therapeutic agents containing such compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/04 A, 7A 61K 31/44 B, 7C 07D 403/04 B, 7C 07D 409/14 B, 7C 07D 407/14 B, 7C 07D 401/14 B, 7C 07D 413/14 B, 7C 07D 417/14 B, 7C 07D 401/04 J, 7C 07D 213:00 J, 7C 07D 207:00 J

A4 Supplementary search report drawn up and despatched

Effective date: 20000128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000823

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030510